Dr. Vigil Gonzales is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
676 N Saint Clair St
Ste 850
Chicago, IL 60611Phone+1 312-695-6180Fax+1 312-695-6189
Summary
- Dr. Carlos Vigil Gonzales is a sub specialized malignant hematologist in Madison ,NJ .He received his medical degree from Cayetano Heredia University and has been in practice for more than 20 years. His main interest is clinical and translational research mainly in myeloid malignancies.
Clinical Expertise
- Myelodysplastic syndromes , Stem cell transplantation, Leukemia, Myeloid leukemia
Education & Training
Vanderbilt University Medical CenterFellowship, Hematopoietic Stem Cell Transplant, 2014 - 2015
M.D. Anderson Cancer CenterFellowship, Leukemia , 2009 - 2010
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2006 - 2009
Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 2003 - 2006
Cayetano Heredia UniversityClass of 2000
Certifications & Licensure
IL State Medical License 2020 - 2026
IA State Medical License 2015 - 2021
NY State Medical License 2010 - 2013
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Clinical Trials
- Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2017 Jul 14
- Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
- A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies Start of enrollment: 2024 Jul 12
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsDifferentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.Pau Montesinos, Amir T Fathi, Stéphane de Botton, Eytan M Stein, Amer M Zeidan
Blood Advances. 2024-05-28 - 8 citationsCrenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.Eunice S Wang, Aaron D Goldberg, Martin Tallman, Roland B Walter, Chatchada Karanes
Journal of Clinical Oncology. 2024-05-20 - 19 citationsTargeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.Stéphane de Botton, Thomas Cluzeau, Carlos Vigil, Rachel J Cook, Philippe Rousselot
Blood Advances. 2023-05-09
Lectures
- Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Professional Memberships
- Fellow
- Member
- Member
- Member
Other Languages
- Spanish, French
Industry Relationships
- Sr Clinical trial Physician, Bristol Myers Squibb
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
